Leonard Post Sells 1,000 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $54.50, for a total transaction of $54,500.00. Following the sale, the director owned 1,000 shares in the company, valued at $54,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CG Oncology Trading Down 4.2%

Shares of NASDAQ CGON opened at $53.72 on Friday. The firm’s 50-day moving average price is $65.98 and its 200-day moving average price is $56.03. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of -23.06 and a beta of 0.31. CG Oncology, Inc. has a 12-month low of $23.65 and a 12-month high of $75.50.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. On average, equities analysts predict that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Analysts Set New Price Targets

CGON has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wolfe Research initiated coverage on shares of CG Oncology in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Wedbush increased their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Finally, Royal Bank Of Canada increased their price objective on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.73.

Institutional Trading of CG Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology in the 4th quarter worth about $27,000. NFSG Corp bought a new position in CG Oncology in the 1st quarter worth about $34,000. Comerica Bank grew its stake in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares in the last quarter. Fifth Third Bancorp bought a new position in CG Oncology in the 1st quarter worth about $74,000. Finally, KBC Group NV bought a new position in CG Oncology in the 1st quarter worth about $78,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.